Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02604173 · ClinicalTrials.gov registry record · Phase 3
Altitude Sickness Prevention and Efficacy of Comparative Treatments
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
NCT02604173: Completed Phase 3 study, sponsored by Stanford University.
NCT02604173 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 103 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02604173, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study is designed to be the first to examine the novel drug budesonide for prevention of acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to high altitude. The investigators will accomplish these objectives with a prospective, double blinded view of a large population of hikers who are ascending at their own rate in a true hiking environment.
Primary Outcome
Number of participants with acute mountain sickness (AMS) by Lake Lousie Questionnaire (LLQ)
Interventions
- DRUG Placebo
- DRUG Acetazolamide
- DRUG Budesonide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2016-08 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
What the finished NCT02604173 record still lists
NCT02604173 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02604173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02604173 about?
NCT02604173 is a clinical study titled "Altitude Sickness Prevention and Efficacy of Comparative Treatments". This study is designed to be the first to examine the novel drug budesonide for prevention of acute mountain sickness in comparison to acetazolamide and in the context of rapid ascent to high altitude. The investigators will accomplish these objectives with a prospective, double blinded view of a la...
What is the current status of trial NCT02604173?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2016-08. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02604173?
The interventions under investigation include: Placebo (DRUG), Acetazolamide (DRUG), Budesonide (DRUG).
Who is sponsoring clinical trial NCT02604173?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02604173's enrollment target sits among peer trials
103 1674th of 2000 higher than 325 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia